{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:18:43Z","timestamp":1786976323777,"version":"build-2736575974"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Evaluate patient\u2010reported outcomes after 6 months of on\u2010label guselkumab use in patients with rheumatologist\u2010diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA\/Spondyloarthritis Registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This analysis includes registry participants who initiated and persisted with on\u2010label guselkumab (after US Food and Drug Administration approval for PsA; 100 mg at weeks 0, 4, and every 8\u2009weeks) at their 6\u2010month follow\u2010up visit (On\u2010Label Persisters). Among patients not meeting response criteria at baseline, responses at 6\u2009months were determined for patient\u2010reported outcomes, including patient\u2010reported pain (0\u2013100\u2009mm visual analog scale), patient global assessment of arthritis + psoriasis (PtGA; 0\u2013100 visual analog scale), and Health Assessment Questionnaire\u2010Disability Index (HAQ\u2010DI; 0\u20103). Unadjusted, nominal\n                      <jats:italic>P<\/jats:italic>\n                      values were calculated via single\u2010proportion, one\u2010sided test (H\n                      <jats:sub>0<\/jats:sub>\n                      =\u20090%; \u03b1\u00a0=\u00a00.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 90 On\u2010Label Persisters, most had treatment\u2010resistant PsA (92.2% and 73.3% previously received \u22651 and \u22652 biologic\/targeted synthetic disease\u2010modifying antirheumatic drugs, respectively), with mean (SD) baseline patient\u2010reported pain, PtGA, and HAQ\u2010DI scores of 57.0 (24.6), 50.3 (24.4), and 0.9\u00a0(0.6), respectively. Among those with patient\u2010reported pain and PtGA scores of at least 15 at baseline, 40.2% (33\/82) and 46.8% (36\/77), respectively, achieved at least 15\u2010mm reductions at 6\u2009months; among those with HAQ\u2010DI scores\u00a0of at least 0.35 and more than 0.5 at baseline, respectively, 30.4% (21\/69) achieved improvements of at least 0.35 and 10.3% (6\/58) achieved scores of 0.5 or lower at 6 months (all nominal\n                      <jats:italic>P<\/jats:italic>\n                      &lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pain and physical function are important contributors to health\u2010related quality of life. In this real\u2010world population of patients with treatment\u2010resistant PsA and 6\u2009months of persistent guselkumab treatment, clinically meaningful improvements in pain and physical function were achieved by approximately 40% and 30% of patients, respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.11657","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T18:29:36Z","timestamp":1709144976000},"page":"304-311","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Improvements in\n                    <scp>Patient\u2010Reported<\/scp>\n                    Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis:\n                    <scp>Real\u2010World<\/scp>\n                    Data From the\n                    <scp>CorEvitas<\/scp>\n                    Psoriatic Arthritis\/Spondyloarthritis Registry"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[{"name":"Rheumatology Research, Providence Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"University of Pennsylvania  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tesser","sequence":"additional","affiliation":[{"name":"Arizona Arthritis &amp; Rheumatology Associates  P.C., Phoenix Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Shiff","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, and University of Saskatchewan  Saskatoon Saskatchewan Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi Sophia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC  Horsham Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, and Drexel University  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kelleman","sequence":"additional","affiliation":[{"name":"CorEvitas, LLC  Waltham Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Dodge","sequence":"additional","affiliation":[{"name":"CorEvitas, LLC  Waltham Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"McLean","sequence":"additional","affiliation":[{"name":"CorEvitas, LLC  Waltham Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Broadwell","sequence":"additional","affiliation":[{"name":"Rheumatology and Osteoporosis Specialists  Shreveport Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"University of California San Diego  La Jolla California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center  Dallas Texas"},{"name":"Brigham and Women's Hospital, Division of Rheumatology and Immunology, Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00635-4"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201163"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160904"},{"key":"e_1_2_8_8_1","volume-title":"TREMFYA\u00ae (guselkumab) injection, for subcutaneous use","year":"2020"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220991"},{"key":"e_1_2_8_12_1","unstructured":"CorEvitas\u00ae. Accessed October 23 2023.www.corevitas.com"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00582-w"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00326-2"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"e_1_2_8_16_1","unstructured":"MeasePJ OgdieA PappasD et al.Prevalence and impact of widespread pain and fibromyalgia on measurement of disease severity in psoriatic arthritis: lessons from the CorEvitas Registry. Abstract presented at: ACR Convergence 2022; November 10\u201014 2022; Philadelphia Pennsylvania."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110546"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000445"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"e_1_2_8_21_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2015.06.018"},{"key":"e_1_2_8_23_1","unstructured":"WalshJ LinI ZhaiR et al.Comparison of on\u2010label treatment persistence in real\u2010world patients with psoriatic arthritis receiving guselkumab versus subcutaneous TNF inhibitors. Poster presented at: Congress of Clinical Rheumatology West; September 7\u201010 2023; San Diego California."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02554-3"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42010"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02269-0"},{"key":"e_1_2_8_28_1","volume-title":"Poster presented at: American Academy of Dermatology Annual Meeting","author":"Fitzgerald T","year":"2023"},{"key":"e_1_2_8_29_1","volume-title":"Poster presented at: American Academy of Dermatology Annual Meeting","author":"Zhdanava M","year":"2023"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2909"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25111"},{"issue":"1","key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/annrheumdis-2023-eular.3988","article-title":"POS1546: Patients with psoriatic arthritis at biologic therapy switch: the CorEvitas Psoriasis Registry","volume":"82","author":"Mease PJ","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.060"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:15:29Z","timestamp":1759418129000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/acr2.11657"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11657","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"2023-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}